07
Oct
2009
Many a seasoned and sophisticated biopharma executive have described to me the reality of when an entity does not need to raise capital it should because at some point it will be needed, and by not needing it, the situation may, just may…lend itself to perhaps lowering the cost of capital due in part to [...]
27
Sep
2009
Now, some 48-hours later, it may be considered old news that Allos Therapeutics (NASDAQ: ALTH) received from FDA accelerated approval for Folotyn™ (pralatrexate) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Folotyn™ is the first and only drug approved by FDA for PTCL and represents a new treatment option for [...]
31
Aug
2009
FDA will seek input from the Oncologic Drugs Advisory Committee on Wednesday 2 September re: review of Allos Therapeutics’ (NASDAQ: ALTH) New Drug Application for pralatrexate (Folotyn); for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. It appears as though reviewers have questioned some findings reported by the Company on the effectiveness [...]
08
Jun
2008
Allos Therapeutics (NASDAQ: ALTH) announced positive interim data from their Phase I dose optimization study of PDX (pralatrexate) with vitamin B12 and folic acid supplementation in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). The data demonstrated activity in a range of doses, and will continue with the objective of determining the optimal dose [...]
20
May
2008
On the heels of Allos Therapeutics (NASDAQ: ALTH) reporting of positive interim data for their pivotal Phase II PDX (pralatrexate) trial, where a 29% of 65 T-cell lymphoma patients had either a complete or partial response, have now unveiled their follow-on financing strategy for ongoing clinical requirements in addition to preclinical R&D of pipeline candidates, [...]
22
Apr
2008
Allos Therapeutics (NASDAQ: ALTH) has completed patient enrollment a quarter ahead of schedule for their Phase II trial of PDX (pralatrexate) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).The pivotal Phase II trial is an international, multi-center, open-label, single-arm study that enrolled patients with relapsed or refractory PTCL who progressed after at least [...]
14
Mar
2008
At the recent year-end call Allos Therapeutics (NASDAQ: ALTH) reported financial and developmental 2007 highlights. As-of 31 December the company had a cash and cash equivalent position of $57.8M on hand, the coffers were achieved primarily via a 1Q07 9M common share offering that raised just north of $50M. With a quarterly burn of approximately [...]
12
Sep
2007
Colorado Public Company News:
Posted in CO Public: Accelr8, CO Public: Allos Therapeutics, CO Public: Array, CO Public: Aspen BioPharma, CO Public: Ceragenix Pharma, CO Public: Encision, CO Public: Heska, CO Public: Tapestry Pharma
By my calculations there are ten publicly traded CO-based life science companies. I will begin a regular update of this group. Another group of public companies are operating in or have other significant interests or relationships with entities in Colorado. This group includes Amgen (NASDAQ: AMGN), Gilead (NASDAQ: GILD), Merck (NYSE: MRK), Roche (VTX: ROG.VX) [...]
01
Feb
2007
Action At Allos
Posted in CO Public: Allos Therapeutics
Lot’s of action transpiring at Allos Therapeutics (NASDAQ: ALTH) since Paul Berns has taken over the reigns. We should expect a $50.5M financing to close tomorrow courtesy of Merrill, where 9M shares of common are being floated at $6 less underwriting fees and expenses, much of which to be gobbled up by Baker Brothers Life [...]
26
Nov
2006
Allos Therapeutics, Inc. (NASDAQ: ALTH) having met all minimum requirements was added to the NASDAQ Biotechnology Index. Being added to an index typically yields an uptick in share price and corresponding market cap as all funds, ETF’s, separate accounts etc. that mirror an index must purchase the newly added position, in this particular case the [...]
14
Nov
2006
Allos Therapeutics, Inc. (NASDAQ: ALTH) announced safety results from its Phase I/II trial of Pralatrexate (PDX) in patients with non-Hodgkin’s lymphoma and Hodgkin’s disease, and from its Phase II study of efaproxyn in patients with unresectable non-small cell lung cancer receiving sequential chemoradiotherapy (S-CRT). Results of the PDX sudy indicate a higher incidence of stomatitis [...]
27
Jul
2006
The FDA has granted Allos Therapeutics (NASDAQ: ALTH) next-generation chemotherapy drug pralatrexate, or PDX, for the treatment of T-cell lymphoma, with an orphan drug designation. An orphan drug designation is assigned to a drug that targets the treatment of a disease with less than 200,000 sufferers in the U.S. The status provides seven years of [...]
10
Mar
2006
Allos Therapeutics, Inc. announced today the appointment of Paul L. Berns as the Company’s President, Chief Executive Officer and a member of the Board of Directors, effective immediately. Mr. Berns brings close to 15 years of pharmaceutical industry experience to Allos. While leading Bone Care International, Inc. from June 2002 until its acquisition by Genzyme, [...]
Life Science Deal Flow PARTNERS
-
